Molecular Biosystems shifted its stock exchange this month after being delisted from the NYSE. The company received notice in September that the NYSE had revised its listing criteria, requiring companies to have total market capitalization and
Molecular Biosystems shifted its stock exchange this month after being delisted from the NYSE. The company received notice in September that the NYSE had revised its listing criteria, requiring companies to have total market capitalization and stockholders equity of not less than $50 million. MBI was unable to meet this requirement, and was delisted on Jan. 4. The company began trading under the new symbol MBIO on NASDs (National Association of Securities Dealers) over-the-counter bulletin board on Jan. 5.
In November, San Diego-based MBI and Palatin Technologies of Princeton, NJ, signed an intent to merge (SCAN 11/24/99). The two firms are in discussions with the Securities and Exchange Commission and their stockholders, and hope to close the deal by April, according to Patricia Sullivan, spokesperson for MBI. If the merger is completed, the new firm will operate under Palatins name and will trade on AMEX.
In other MBI news, the company announced last month that Chugai Pharmaceuticals of Tokyo has paid MBI $2 million as Chugai starts clinical trials with Optison for assessment of left ventricular opacification and myocardial perfusion.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.